Discover key strategies for overcoming variability and scalability challenges in AAV production for gene therapy. This poster by Viralgen highlights comparability studies, process changes, and scaling solutions to ensure product quality, safety, and efficacy.
Resources
September 05, 2024
Fast Facts: Navigating variability and scalability challenges in AAV production
Explore more
Insights
Viralgen Vector Core and Elpida Therapeutics partner to manufacture gene therapy medicines for anticipated Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) clinical trials Trial participants with Spastic Paraplegia 50...
READ MORE
September 29, 2023

Insights
Last week, we participated in the ASGCT 26th Annual Meeting, which was held in Los Angeles. We are grateful for a successful meeting at ASGCT and would like to thank all our booth visitors, customers who took time out to meet with the team, and...
READ MORE
May 24, 2023

Insights
ASGCT 26th Annual Meeting starts in a few days. This year, it will be held in Los Angeles from May 16 to 20, and Viralgen will be present at booth 123. The American Society of Gene and Cell Therapy's (ASGCT) Annual Meeting is the premier event for...
READ MORE
April 14, 2023